156 related articles for article (PubMed ID: 18850301)
1. Potential efficacy of enzyme replacement and substrate reduction therapy in three siblings with Gaucher disease type III.
Cox-Brinkman J; van Breemen MJ; van Maldegem BT; Bour L; Donker WE; Hollak CE; Wijburg FA; Aerts JM
J Inherit Metab Dis; 2008 Dec; 31(6):745-52. PubMed ID: 18850301
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
[TBL] [Abstract][Full Text] [Related]
3. Gaucher disease: variability in phenotype among siblings.
Amato D; Stachiw T; Clarke JT; Rivard GE
J Inherit Metab Dis; 2004; 27(5):659-69. PubMed ID: 15669682
[TBL] [Abstract][Full Text] [Related]
4. Imiglucerase low-dose therapy for paediatric Gaucher disease--a long-term cohort study.
Heitner R; Arndt S; Levin JB
S Afr Med J; 2004 Aug; 94(8):647-51. PubMed ID: 15352589
[TBL] [Abstract][Full Text] [Related]
5. Outcome of type III Gaucher disease on enzyme replacement therapy: review of 55 cases.
Davies EH; Erikson A; Collin-Histed T; Mengel E; Tylki-Szymanska A; Vellodi A
J Inherit Metab Dis; 2007 Nov; 30(6):935-42. PubMed ID: 17994286
[TBL] [Abstract][Full Text] [Related]
6. Combined miglustat and enzyme replacement therapy in two patients with type 1 Gaucher disease: two case reports.
Amato D; Patterson MA
J Med Case Rep; 2018 Jan; 12(1):19. PubMed ID: 29373994
[TBL] [Abstract][Full Text] [Related]
7. Ten years' experience of enzyme infusion therapy of Norrbottnian (type 3) Gaucher disease.
Erikson A; Forsberg H; Nilsson M; Aström M; Månsson JE
Acta Paediatr; 2006 Mar; 95(3):312-7. PubMed ID: 16497642
[TBL] [Abstract][Full Text] [Related]
8. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease.
Schiffmann R; Heyes MP; Aerts JM; Dambrosia JM; Patterson MC; DeGraba T; Parker CC; Zirzow GC; Oliver K; Tedeschi G; Brady RO; Barton NW
Ann Neurol; 1997 Oct; 42(4):613-21. PubMed ID: 9382473
[TBL] [Abstract][Full Text] [Related]
9. Baseline characteristics and outcome in Romanian patients with Gaucher disease type 1.
Grigorescu-Sido P; Drugan C; Alkhzouz C; Zimmermann A; Coldea C; Denes C; Grigorescu MD; Cret V; Bucerzan S
Eur J Intern Med; 2010 Apr; 21(2):104-13. PubMed ID: 20206881
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Evaluation of Biomarkers in the Czech Cohort of Gaucher Patients.
Malinová V; Poupětová H; Řeboun M; Dvořáková L; Reichmannová S; Švandová I; Murgašová L; Kasper DC; Magner M
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37833892
[TBL] [Abstract][Full Text] [Related]
11. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary involvement in siblings with Gaucher disease type III.
Djordjević M; Minić P; Sarajlija A; Djuricic SM; Djokić D; Marković O
Vojnosanit Pregl; 2011 Dec; 68(12):1071-4. PubMed ID: 22352271
[TBL] [Abstract][Full Text] [Related]
13. Enzyme replacement therapy for Gaucher disease in Australia.
Goldblatt J; Szer J; Fletcher JM; McGill J; Rowell JA; Wilson M
Intern Med J; 2005 Mar; 35(3):156-61. PubMed ID: 15737135
[TBL] [Abstract][Full Text] [Related]
14. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress, trace elements, and circulating microparticles in patients with Gaucher disease before and after enzyme replacement therapy.
Zahran AM; Elsayh KI; El-Deek SE; El-Baz MA
Clin Appl Thromb Hemost; 2015 Jan; 21(1):58-65. PubMed ID: 23698728
[TBL] [Abstract][Full Text] [Related]
16. Outcome of enzyme replacement therapy in Turkish patients with Gaucher disease: does late intervention affect the response?
Arikan-Ayyildiz Z; Yüce A; Emre S; Baysoy G; Saltik-Temizel IN; Gürakan F
Turk J Pediatr; 2011; 53(5):499-507. PubMed ID: 22272449
[TBL] [Abstract][Full Text] [Related]
17. Glucosylsphingosine is a key biomarker of Gaucher disease.
Murugesan V; Chuang WL; Liu J; Lischuk A; Kacena K; Lin H; Pastores GM; Yang R; Keutzer J; Zhang K; Mistry PK
Am J Hematol; 2016 Nov; 91(11):1082-1089. PubMed ID: 27441734
[TBL] [Abstract][Full Text] [Related]
18. [Comparison and clinical application of two methods for determination of plasma chitotriosidase activity].
Wang Y; Zhang HW; Ye J; Qiu WJ; Han LS; Gu XF
Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):834-8. PubMed ID: 23302614
[TBL] [Abstract][Full Text] [Related]
19. Early initiation of ambroxol treatment diminishes neurological manifestations of type 3 Gaucher disease: A long-term outcome of two siblings.
Ramadža DP; Zekušić M; Žigman T; Škaričić A; Bogdanić A; Mustać G; Bošnjak-Nađ K; Ozretić D; Ohno K; Fumić K; Barić I
Eur J Paediatr Neurol; 2021 May; 32():66-72. PubMed ID: 33836415
[TBL] [Abstract][Full Text] [Related]
20. Relationship Between Glucocerebrosidase Activity and Clinical Response to Enzyme Replacement Therapy in Patients With Gaucher Disease Type I.
Gras-Colomer E; Martínez-Gómez MA; Climente-Martí M; Fernandez-Zarzoso M; Almela-Tejedo M; Giner-Galvañ V; Marcos-Rodríguez JA; Rodríguez-Fernández A; Torralba-Cabeza MÁ; Merino-Sanjuan M
Basic Clin Pharmacol Toxicol; 2018 Jul; 123(1):65-71. PubMed ID: 29418074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
